DOCS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -12.41%, SMA50 -32.47%, SMA200 -54.39%). The stock’s 14-day RSI is 25.81 (weak momentum), while the ATR of 1.67 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -67.19% below its high and over 6.67% above its low. Average 10-day trading volume of 2.93 million shares is below the 3-month average of 3.57 million, indicating normal recent market interest.

Doximity, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $28.12. This means the shares are trading below this model’s fair value.

Doximity, Inc. has 136.40 million shares outstanding. The public float is 133.22 million shares, elevated short interest at 3.52% of float. This equals 4.70 million shares. The short ratio is 2.62 days. Institutional investors hold 92.64% of the float. Insiders own 2.29%. Tangney Jeffrey holds 2.10 million shares, EMERGENCE CAPITAL PARTNERS II LP has 775.00 thousand shares and Spain Kevin has 775.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 24.60 thousand shares across 8 transactions.

Doximity, Inc. (NYSE:DOCS) closed at $24.64 USD, gaining $0.75 (3.12%) from the previous close of $23.90. The stock is currently mid-range between its 52-week high and low $20.55 and $76.51. With a market capitalization of about $4.63 billion, Doximity, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.42). Key stats such as the average daily volume over the past year has been around 3.55 million shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Doximity, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Jeffrey A. Tangney, the company employs approximately 827 people and listed since June 24, 2021. Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States.

Doximity, Inc. generated EPS of $1.19 over the past year. Five-year average earnings growth is 79.45%. Wall Street analysts project EPS growth of 8.55% annually over the next five years. The latest quarter delivered EPS of $0.45. The next quarter is forecast at $0.28. Next year's EPS is expected at $5.83. Analyst sentiment is bullish. Analyst rating data shows there are 20 Strong Buy ratings, 7 Buy ratings, 14 Hold ratings, 1 Sell rating and 1 Strong Sell ratings. Price targets range from $81.00 to $25.00. The high target offers 264.04% upside. The low target suggests 12.36% downside. The mean target is $55.74. This offers 150.52% upside. Doximity, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 18.42%. The prior quarter beat by 19.36%. Over the last six quarters, Apple has recorded several small beats. These include 27.27% in August 08, 2024.

Doximity, Inc. trades at a P/E ratio of 17.28, slightly below the S&P 500 average, with a price-to-sales ratio of 6.5 and a price-to-book ratio of 4.22 trading at moderately above to book value. The P/FCF stands at 13.3, also below market averages.

Doximity, Inc. (NYSE:DOCS) shares are flat -7.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Doximity, Inc. trading at a premium to the broader market with a P/E of 17.28. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $51.89, suggesting 133.21% upside. Our AI forecast model points to short-term weakness (-8.54% over two weeks), a medium-term fall (-18.34% over three months), and a longer-term gain (73.48% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Doximity, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.54%, with price expected at $20.35 by April 28, 2026, within a range of $19.64 to $21.11 3-Month Outlook: Projected fall of -18.34%, reaching $18.17 by July 13, 2026, with a range of $16.60 to $19.56. 1-Year Outlook: Projected gain of 73.48%, with price at $38.60 by April 14, 2027, within a range of $33.62 to $43.30.